{
    "id": 29159,
    "fullName": "AFAP1 - NTRK1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "AFAP1-NTRK1 results from the fusion of AFAP1 and NTRK1 (PMID: 30333516). AFAP1-NTRK1 has been associated with glioblastoma (Cancer Res 2017;77(13 Suppl):Abstract nr LB-302), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 13475,
                    "pubMedId": null,
                    "title": "Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/LB-302"
                },
                {
                    "id": 13476,
                    "pubMedId": 30333516,
                    "title": "NTRK fusion-positive cancers and TRK inhibitor therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333516"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 60312,
        "geneSymbol": "AFAP1",
        "terms": [
            "AFAP1",
            "AFAP",
            "AFAP-110",
            "AFAP110"
        ]
    },
    "variant": "AFAP1 - NTRK1",
    "createDate": "01/04/2019",
    "updateDate": "10/03/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15629,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NAVIGATE), Vitrakvi (larotrectinib) treatment resulted in evidence of effect by imaging in a patient with glioblastoma multiforme harboring AFAP1-NTRK1 (Cancer Res 2017;77(13 Suppl):Abstract nr LB-302).",
            "molecularProfile": {
                "id": 31095,
                "profileName": "AFAP1 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13475,
                    "pubMedId": null,
                    "title": "Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/LB-302"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31095,
            "profileName": "AFAP1 - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 19320,
                    "name": "Larotrectinib",
                    "profileName": "AFAP1 - NTRK1"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}